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Abstract
Purpose of the Review Causality has been demonstrated for few of the many putative risk factors for type 2 diabetes (T2D)
emerging from observational epidemiology. Genetic approaches are increasingly being used to infer causality, and in this review,
we discuss how genetic discoveries have shaped our understanding of the causal role of factors associated with T2D.
Recent Findings Genetic discoveries have led to the identification of novel potential aetiological factors of T2D, including the
protective role of peripheral fat storage capacity and specific metabolic pathways, such as the branched-chain amino acid
breakdown. Consideration of specific genetic mechanisms contributing to overall lipid levels has suggested that distinct phys-
iological processes influencing lipid levels may influence diabetes risk differentially. Genetic approaches have also been used to
investigate the role of T2D and related metabolic traits as causal risk factors for other disease outcomes, such as cancer, but
comprehensive studies are lacking.
Summary Genome-wide association studies of T2D and metabolic traits coupled with high-throughput molecular phenotyping
and in-depth characterisation and follow-up of individual loci have provided better understanding of aetiological factors con-
tributing to T2D.
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Introduction
The Urgency to Prioritise Proposed Risk Factors
For very few of the many type 2 diabetes (T2D) risk factors
[1–6, 7•] that have emerged from observational research has
causal relevance been demonstrated [8–12]. Randomised con-
trolled trials are the “gold-standard” for causality assessment
but are expensive and time-consuming, and may not be feasi-
ble (e.g. birth weight, epigenetic markers) or ethical (e.g.
alcohol consumption, smoking) for some exposures.
Examples of high-profile failures to replicate interventions
that were prioritised on the basis of observational evidence
highlight the limited ability of even rigorously conducted ob-
servational epidemiological studies to control the influence of
bias and confounding and allow inference about causality of
the observed statistical associations [13, 14]. While risk fac-
tors that are not causally associated with a disease, for exam-
ple markers of the subclinical disease process, can be useful
for disease prediction, this is not the case if the aim is to
identify targets for intervention. Hence, new ways to prioritise
risk factors on the basis of their causal likelihood are needed.
Genetic Approaches to Assess Causality
Genetic evidence through genotyping and sequencing of pa-
tients is expected to reduce the high rate of late-stage failures
in drug development to translate laboratory models into the
clinic [15–17]. Similarly, genetic insights may help to gener-
ate evidence about causal relevance and prioritise risk factors
for testing in trials. Genetic approaches can support causal
inference because genetic variants are generally less correlated
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with many of the measured and unmeasured factors that can
confound observational exposure-to-disease associations, pro-
vided important assumptions are met (Fig. 1). This genetic
approach to causal inference, referred to as “Mendelian
randomisation”, was originally proposed for the investigation
of the association between fibrinogen and coronary heart dis-
ease by Keavney [18] and has since gained popularity and
been the subject of many investigations and reviews
[19–22]. Genetic approaches to estimate causal effect sizes
require estimates of genetic associations with exposures of
interest and outcomes. For many risk factors, these data have
already been generated through genome-wide association
studies (GWAS), and results for T2D are publically available
via the online type 2 diabetes knowledge portal (http://www.
type2diabetesgenetics.org) [23]. Therefore, the cost and time
investment is relatively small, specifically considering the
costs, duration and participant burden of trials.
GWAS of T2D have clearly demonstrated the importance
of established aetiological pathways, specifically pancreatic
beta cell function, adiposity and insulin resistance [24••, 25,
26•]. This suggests that hypothesis-free genetic approaches
provide a useful tool to identify and assess causality of novel
disease mechanisms.
Outline
This review focuses on aetiological pathways of T2D emerg-
ing from large-scale GWAS and richly phenotyped epidemio-
logical studies, using three illustrative examples. We outline
how recent genetic research has revealed a complex role of
lipid metabolism in the aetiology of diabetes and has proposed
peripheral fat storage capacity as a protective factor for T2D.
We then describe how genetics can help to identify and
prioritise causal pathways among the multitude of established
and emerging biomarkers. Finally, we highlight the opportu-
nities to use insights into the genomics of diabetes to infer its
relevance as a causal risk factor for other common serious
conditions, such as cancer.
The Central Role of Peripheral Fat
Overall Adiposity and Fat Distribution Both Affect
Diabetes Risk
Obesity is a strong modifiable risk factor for T2D [8–12] and
responsible for the secular increase in the diabetes prevalence,
with three quarters of people with diabetes now living in low-
and middle-income countries [27]. Weight loss interventions
reduce diabetes risk [8–12] and are even able to revert
glycaemia in patients with T2D to non-diabetic levels [28].
Genetic evidence supports the causal role of overall adiposity;
the major bodymass index (BMI) locus near FTOwas the first
found to exert its diabetes risk-raising effect entirely by in-
creasing BMI. More recently, the largest European ancestry-
focused GWAS of T2D, which tested 27 million variants and
included more than 74,000 cases showed that 26 of the more
than 400 conditionally independent variants at the identified
loci for T2D predominantly increase risk through their effect
on BMI, including established adiposity loci such as FTO,
MC4R and TMEM18 [24••]. Independent causal roles of over-
all adiposity and abdominal fat accumulation has also been
supported by Mendelian randomisation studies [29•, 30, 31•].
Genetic Loci Link Low Adiposity to High Diabetes Risk
Evidence is emerging that not all mechanisms leading to re-
duced fat accumulation are uniformly beneficial to metabolic
health. Loci near IRS1 and COBLL1/GRB14 identified for
lower total body fat percentage were found to be associated
with higher risk of T2D [32•, 33]. Similarly, a coding variant
in the CREBRF gene was found to increase BMI by 1.32–
1.46 kg/m2 per allele but reduce diabetes risk by 40% in a
Polynesian population [34•]. In line with this, the most recent
T2D GWAS showed that associations for a subset of loci were
strengthened following adjustment for body mass index;
among these were signals previously shown to be associated
with lower capacity of adipose tissue generation and expan-
sion [35••], including PPARG—a gene involved in Mendelian
forms of partial lipodystrophy [36]. Together, these results
suggest that, when focussing on distinct pathways connecting
adiposity and diabetes, certain biological processes may re-
duce fat accumulation while increasing risk of T2D, while
others will reduce risk.
Lipodystrophy-Like Mechanisms May Contribute
to Insulin Resistance
Genetic research on metabolic risk factors demonstrated that
distinct pathways linking low adiposity to diabetes risk may
be driven by insulin resistance. It was recognised early on that
discovery of loci associated with insulin resistance was facil-
itated by accounting for differences in obesity levels [37];
GWAS of insulin resistance have since been conducted based
on fasting insulin levels adjusted for BMI [35••, 37–39].
Research on the relationship between insulin resistance and
refined measures of body composition measured by dual en-
ergy X-ray absorptiometry (DEXA) showed associations be-
tween genetic determinants of insulin resistance and reduced
fat accumulation in the legs and other peripheral compart-
ments [35••, 39]. Positive relationships of insulin resistance
with visceral fat mass and liver enzymes [35••, 39, 40] sug-
gested that genetic predisposition to insulin resistance, not
primarily driven by a long-term positive energy balance, is
linked to a body fat distribution pattern that favours visceral
and ectopic fat deposition over deposition in peripheral body
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compartments. Questions remain on whether impaired periph-
eral fat and enhanced central fat distribution are independent
mechanisms.
Lotta et al. found that the 53 loci associated with hallmarks
of common insulin resistance are also enriched in patients
with familial partial lipodystrophy type 1, which is a rare
condition characterised by extreme insulin resistance and the
limited ability to store fat peripherally [35••]. These loci iden-
tified for common insulin resistance were enrichedwith causal
genes involved in monogenic forms of lipodystrophy, includ-
ing PPARG, PIK3R1 and INSR [41]. This suggests the pres-
ence of shared mechanisms between common and rare forms
of insulin resistance, and that lipodystrophy-like mechanisms
may contribute to common forms of insulin resistance and
metabolic and cardiovascular disease.
The majority of genetic studies have been conducted in
participants of European ancestry. Many people who develop
T2D in South-East Asia, the middle East and sub-Saharan
Africa are not overweight or obese [42–44]. Ethnicity-specific
patterns of fat distribution may underlie differences in meta-
bolic risk for a given BMI, but the causal role of the relative
contributions of greater abdominal and lack of gluteo-femoral
fat have not been investigated.
The Adipose Tissue Expandability Hypothesis
Altogether, these findings support the so-called adipose tissue
expandability hypothesis, which states that each individual has
a limited capacity to store excess energy in adipose tissue; once
that threshold has been reached, excess energy in the form of
lipids may accumulate ectopically in diabetes-relevant tissues
such as the liver, muscles and the pancreas, where they may
contribute to tissue dysfunction and diminished insulin action
[45, 46]. Individuals with a larger capacity to peripherally ac-
cumulate fat may therefore be more protected from the cardio-
metabolic consequences of a long-term positive energy bal-
ance. In support of this hypothesis, longitudinal data on weight
change have demonstrated that people with a higher burden of
insulin resistance-increasing alleles tend to expand their hip fat
depot less as they gain weight than people at low genetic risk to
develop insulin resistance [35••]. Refined imaging methods,
including DEXA andmagnetic resonance imaging (MRI), will
help to further confirm this hypothesis and the specific contri-
bution of these mechanisms to the broader relationship be-
tween fat distribution and metabolic risk in men and women
and across ethnic groups.
The Complex Interplay between Blood Lipid
Fractions and T2D
Genetics-Based Causality Assessments of Blood Lipids
as Diabetes Risk Factors
After meta-analyses of randomised controlled trials of statins
revealed that this major class of low-density lipoprotein
cholesterol-lowering drugs modestly increases risk of T2D
[47], a series of genetic studies focussing on the contribution
of lipid fractions to diabetes risk was conducted. Early genetic
studies investigating the causality of the blood lipid fractions
focussed on the individual, separate contributions of three
major lipid fractions: total triglycerides, high-density lipopro-
tein (HDL) and low-density lipoprotein (LDL) cholesterol
[48–50]. Because levels of these fractions are regulated by
partially overlapping physiological processes, genetic scores
were not specific to one lipid fraction only, and therefore,
Fig. 1 Schematic overview of theMendelian randomisation (MR) framework. βvar-RF: per-allele effect size of genetic variant on risk factor; βvar-T2D: per-
allele effect size of genetic variant on T2D
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specific causal inference is limited. To disentangle the causal
effect of genetically related risk factors, the so-called multi-
variable Mendelian randomisation methods have been devel-
oped [51•], which estimate independent effect sizes of genet-
ically correlated risk factors on the outcome in one model by
taking the genetic correlation between them into account.
High HDL cholesterol has been consistently associated with
lower incidence of T2D, both observationally [52–54] and in
multivariable Mendelian randomisation studies [55••, 56••],
but recent evidence highlights that the extent to which LDL
cholesterol and total triglyceride levels influence diabetes risk
may be mechanism-dependent.
Complex Relationships between LDL Cholesterol
and Diabetes Risk
While there is no doubt that higher LDL cholesterol increases
the risk of diseases of the heart and vasculature, strong evi-
dence is now available that some mechanisms lowering LDL
cholesterol increase the risk of T2D [55••, 56••]. Using mul-
tivariable Mendelian randomisation, two recent publications
suggested that higher levels of LDL cholesterol are causally
related to lower diabetes risk, in line with evidence of statin
trials, [47] and a study of patients with familial hypercholes-
terolaemia, reporting a lower incidence of T2D, compared to
their unaffected family members [57]. In contrast, familial
hypercholesterolaemia was not associated with lower diabetes
risk in an Amish population [58]. Differences in the genetic
background, identification and management of these Dutch
and Amish patient populations may have contributed to these
discrepant findings.
The extent to which levels of LDL cholesterol influence
diabetes riskmay depend on the physiological mechanism that
contributes to differences in lipid levels [59••, 60••]. For a
given effect on LDL, the effect size of the associations be-
tween genetically predicted LDL cholesterol and T2D was
shown to differ depending on the gene in which LDL variants
are located when variants in current or prospective LDL-
lowering drug targets, including PCSK9, HMGCR, NPC1L1,
ABCG5/G8 and LDLR, were compared [59••]. This is in con-
trast to the effect of LDL cholesterol on risk of coronary
heart disease, which follows a clear log-linear pattern, in
observational, genetic [59••, 61] and intervention studies
[62].
The Role of Total Triglycerides May Be
Mechanism-Dependent
Although total triglycerides have been consistently associated
with higher incidence of T2D [52–54], results for total triglyc-
erides from genetics-based causal assessments are inconsistent
[55••, 56••]. Genetic evidence suggests that triglycerides may
be protective or detrimental for diabetes risk, depending on the
physiological mechanism driving triglyceride levels.
Triglyceride-lowering genes involved in intravascular lipoly-
sis, including intravascular lipoprotein lipase (LPL) and its
inhibitor angiopoietin-like 4 (ANGPTL4), have been associat-
ed with lower risk of T2D [35••, 60••], while triglyceride-
lowering variants in genes involved in the hepatic production
of triglyceride-rich lipoprotein particles were linked to higher
risks of diabetes and fatty liver [60••]. In contrast, there is
strong genetic evidence that several triglyceride-raising mech-
anisms are causally related to risk of coronary heart disease
[60••, 63, 64].
These recent findings demonstrate how different genetic
approaches can help to investigate and better understand the
complex relationships between dyslipidaemia and diabetes
risk by looking not only at risk factor levels, but specific
mechanisms underlying these differences. Investigation of
combined genetic scores that encompass a large range of bio-
logical mechanisms affecting overall lipid concentrations may
help general inference about causality of the exposure in ques-
tion but cannot reveal insight into the complexity underlying
the regulation of lipid metabolism. Given that LDL loci (for a
given effect on LDL) differed in their association with diabe-
tes risk, locus-specific results may also help to better estimate
the effect of interventions that target levels through different
mechanisms will have on different outcomes. Pleiotropy and
heterogeneity of genetic loci is considered a limitation of
Mendelian randomisation, but studies on the role of lipid me-
tabolism for diabetes aetiology highlight that biologically rel-
evant insights can be obtained by investigating individual ge-
netic loci that are pleiotropic or have, given their effect on the
exposure, a disproportionate effect size on the outcome.
Genetics to Prioritise Causal Pathways
Amongst the Multitude of Reported
Biomarker Associations
Biomarkers as Causal Candidates
Interest into the potential causality of biomarkers for T2D has
grown, as they can point to novel disease pathways and help to
identify potential targets for intervention, provided they are
causal. A systematic literature review has shown that more
than 160 biomarkers measured in blood or urine have been
proposed to be associated with T2D, but for a small minority
has an assessment of causality been attempted [7•]. No evi-
dence for causality was found for the majority of the bio-
markers that have been investigated using genetic approaches,
including Vitamin D [65], adiponectin [66, 67], uric acid [68],
C-reactive protein [69] and gamma-glutamyl transferase
[70–72]. However, for a few biomarkers, including sex
hormone-binding globulin [73, 74], B and A-type natriuretic
peptide systems [75, 76] and bilirubin [77], suggestive
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evidence for a causal relationship with T2D has been reported.
Historically, some of the older studies investigating one bio-
marker at a time were based on comparatively small sample
sizes and a limited understanding of the specificity of the
genetic score. Replication of these findings is needed using
genetic prediction models that maximise exposure variance
explained, utilise largest available GWAS summary statistics,
test generalisability across different ancestries where possible
and investigate specificity of genetic variants in adequately
powered studies with comprehensive coverage of relevant bi-
ological pathways.
New Wave of Omics-Based Biomarkers
Technological developments in “-omics” methods have
enabled high-throughput assessment of molecular traits
in large epidemiological studies, including the metabo-
lome, proteome and lipidome. This has led to a new wave
and scale of observational diabetes “biomarker” discover-
ies, including metabolites [78–82], lipid species [83–86],
proteins [87] and methylation markers [88•]. Molecular
traits, such as metabolites, often represent the same bio-
logical pathway; therefore, large subsets of traits can be
strongly correlated with each other. Cohort studies
assessing different outcomes have shown that individual
molecular traits tend to be associated with multiple dis-
ease outcomes [89–91]. The lack of specificity with re-
gard to the exposure and outcome highlights that large-
scale parallel biomarker assessment in an observational
setting is subject to the same limitations as traditional
biomarker studies and is even more prone to false-
positive discovery by multiple testing. Integration of ge-
netic data can be a helpful tool to prioritise potential caus-
al pathways from the dense network of molecular trait-to-
disease outcome associations.
Omics Integration
GWAS have been conducted on the metabolome [92–94],
proteome [95••] and methylome [96], with larger scale ef-
forts underway. Results of these studies show that, due to
the close biological proximity, genetic loci explain large
proportions of the variance of a given marker and relevant
biological mechanisms can be identified in relatively small
sample sizes. For example, in a recent study on the genetic
architecture of the human plasma proteome, GWAS were
conducted for nearly 3000 proteins, based on 3000 partic-
ipants [95••]. Despite the relatively modest sample size,
more than 1900 genetic associations with 1478 proteins
were found, and 66% of the identified regions influenced
protein levels encoded by nearby genes. The median vari-
ance in protein levels explained by the variants was 5.8%
(interquartile range 2.6–12.4%), which is similar the total
variance in BMI explained by over 550 signals identified
in a GWAS of around 700,000 participants [97].
Integration of genetic markers with large-scale molec-
ular phenotyping can enable the identification of novel,
molecular aetiological pathways. For example, GWAS in
combination with metabolomics was recently used to
assess the causality of the widely reported associations
between branched-chain amino acids and incidence of
T2D [89]. Based on a genetic score including variants
in the PPM1K gene encoding the activator for the en-
zyme catalysing the rate-limiting step in branched-chain
amino acid breakdown, evidence was found that
branched-chain amino acid catabolism and T2D may
be bidirectionally causally related [98•]. In another
study, evidence based on cis-acting genetic markers
was found that the protein marker macrophage
metalloelastase 12 (MMP-12) may protect against coro-
nary heart disease, while observational studies suggested
a positive association [95••]. This finding suggests po-
tential safety issues for MMP-12 inhibitors, which are
being developed for the treatment of chronic obstructive
pulmonary disease. Finally, Elliott et al. identified ge-
netic loci associated with methylation markers previous-
ly associated with T2D and used these as genetic instru-
ments to distinguish methylation markers that may be
on the causal path to T2D from those that are likely
to be non-causal [99••]. Their results suggested that
the vast majority of methylation markers for diabetes
are unlikely to be causal, with the exception of a meth-
ylation site at the KCNQ1 locus [99••].
As -omics technologies are becoming more widely imple-
mented in epidemiological studies of increasing size, oppor-
tunities to obtain an even more comprehensive insight into
disease mechanisms may arise by integrating multiple layers
of -omics data.
The Causal Interplay between Diabetes,
Metabolic Risk Factors and Cancer Incidence
Obesity [100] and T2D [101] have been linked to
higher incidence of several cancers, but the causal role
of metabolic health in cancer risk is difficult to assess
observationally due to bias and confounding. Ongoing
efforts by the Meta-Analyses of Glucose and Insulin-
related traits Consortium (MAGIC) and others continue
to improve our understanding of the genetic determi-
nants of phenotypes associated with adiposity and T2D
that are likely to contribute to the links between obesity,
T2D and cancer. Application of these discoveries to
results from GWAS identifying germline variants asso-
ciated with site-specific cancer risk may help to refine
our understanding of relevant pathways and identify
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appropriate preventative interventions. Such efforts crit-
ically depend on willingness and ability to make
genome-wide summary statistics accessible for re-
searchers in a timely manner. As mentioned above, the
T2D research community systematically contributes new
findings to an openly accessible online knowledge plat-
form [23]. A similar dedicated online platform for can-
cer GWAS summary results and a more systematic de-
position of GWAS summary results to existing online
tools such as Phenoscanner (http://www.phenoscanner.
medschl.cam.ac.uk/phenoscanner) [102] or MR Base
(www.mrbase.org) [103] would be of great benefit to
the scientific community and facilitate rapid and
comprehensive investigation of the links between
metabolic risk factors and cancer across different
cancer sites and types.
Genetics-based research has proposed adiposity and in-
sulin resistance as causal risk factors for specific types of
cancer. Adiposity, insulin resistance and secretion have all
been shown to be causally related to endometrial cancer
risk, the site most strongly associated with obesity obser-
vationally [104, 105]. For breast cancer, a protective ef-
fect of body mass index in both pre- and post-menopausal
breast cancer has been reported [106], but no causal role
for T2D was found [107, 108]. Genetically predicted in-
sulin resistance has also been associated with lung [109•]
and pancreatic cancer [110], whereas genetically predicted
BMI has been linked to higher risk of colorectal [111•],
pancreatic [110] and lung cancer [109•].
These early genetics-based studies suggest that dis-
tinct metabolic risk factors may be causal for different
types of cancer, but comprehensive investigations that
assess the role of a range of refined metabolic risk
factors across cancer types are still lacking.
Conclusion
Rapid progress in the identification of the genetic basis of
T2D and related phenotypes, together with technological
advances that facilitate high-throughput and refined pheno-
typing at scale, provide important opportunities for epide-
miological research to identify novel aetiological pathways
and enhance causal understanding of potential risk factors
that are amenable to intervention. Better powered studies
now provide greater sensitivity to investigate pleiotropy
that may have previously been overlooked and may have
confounded effect sizes of genetically predicted exposures.
Traditional genetic approaches to infer causality have gen-
erally focused on average effects, sometimes estimated
from large polygenic scores. Recent examples have
highlighted opportunities that arise from distinguishing
the effects of specific mechanisms represented by a locus
or a subset of loci, which may otherwise be overlooked.
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